NextGen NextGen NextGen

NextGen Medicine basket and the protein folding problem

PG
Peter Garnry

Head of Equity Strategy

Summary:  DeepMind's AlphaFold algorithm for predicting the 3D shape of protein folding is one of the biggest scientific breakthroughs in biology the last 50 years and solves a long standing problem. The breakthrough will likely lead to the Nobel Prize in chemistry and advance drug discovery on a scale we could only dream of a decade ago. AlphaFold underpin why our NextGen Medicine basket is such an important theme for investors to be exposed to long-term as biotechnology companies could end up being the big winners over the next couple of decades.


DeepMind’s gift to humanity will unleash massive innovation in medicine

In the midst of a global pandemic the world experienced two major breakthroughs in medicine and biochemistry in November 2020. First, Pfizer with its partner BioNTech announced a highly effective vaccine against Covid-19 using mRNA technology for the first time ever in history; it became the fastest developed vaccine in the world. Later during the month Nature announced a ground-breaking scientific discovery from Google’s AI unit DeepMind in which the company’s deep learning algorithm called AlphaFold is able to predict the 3D shape of proteins. Scientists agreed that “It will change everything” and DeepMind chose to make their AlphaFold Protein Structure Database available for free to all scientists.

Around 20 months later DeepMind went a step further announcing that it has, in collaboration with the European Bioinformatics Institute, catalogued nearly all protein known in the universe expanding the database of protein structures from 1 to 200 million structures. Before AlphaFold experimental work had unveiled around 190,000 protein structures. This new database gifted to humanity will advance our understanding of biology and potentially lead to quantum leaps in drug discovery. DeepMind’s scientific breakthrough solves the 50-year problem of protein folding and will most likely lead to the Nobel Prize in Chemistry.

Investors must have exposure to “biology” in their long-term portfolios

The 21st century has often been labelled the century of biology in which computational biology and breakthroughs such as AlphaFold will deliver better and faster drugs to combat diseases. Our NextGen Medicine basket consists of 30 companies representing the long tail of innovation inside the biotechnology industry which today is dominated by a group of very large and successful companies such Amgen, Gilead Sciences, and Vertex Pharmaceuticals etc. Our focus has been on some of the newer technologies within biotechnology such as mRNA, gene therapy, gene editing etc.

The world’s leading biotechnology index which tracks the largest and most liquid biotechnology companies is called NASDAQ Biotechnology Index and it has returned 9.7% annualised since late 2003 compared to 8.1% for MSCI World Index generating 1.6% annualised alpha. The amount of alpha has shrunk considerably the past year as rising interest rates has pushed down equity valuations of high duration assets (companies with high valuation or no earnings) and made financing more difficult.

With the type of drug discovery that might derive from AlphaFold and increased understanding of proteins will make biotechnology as massive and very profitable trend over the coming decades. Microsoft and the computer industry have generated 5-10% annualised alpha since the late 1980s and we believe biotechnology will ultimately do the same catapulting some of these companies into the top ranks of equity indices in terms of market value. One can invest in the stocks in our theme basket but requires decent amount of due diligence and it comes with the risks of not choosing the winners. An alternative is ETFs such as the iShares Nasdaq Biotechnology UCITS ETF (2B70:xetr) tracking the main benchmark index within biotechnology or the Global X Genomics & Biotechnology UCITS ETF (GNOM:xmil) which closer mimics our NextGen Medicine basket.

NameMkt Cap (USD mn.)Sales growth (%)R&D in % of mkt capDiff to PT (%)5yr return
Moderna Inc72,955227.63.36.1NA
BioNTech SE43,313831.02.433.9NA
Illumina Inc35,04934.03.735.014.7
Seagen Inc32,274-25.44.24.6256.0
Genmab A/S23,386-16.519.22.787.0
Argenx SE20,279-74.41.99.51,930.3
Exact Sciences Corp8,42213.34.449.723.0
Grifols SA8,3360.14.358.4-38.5
Swedish Orphan Biovitrum AB6,75121.032.912.684.7
CRISPR Therapeutics AG6,08783,039.37.745.1327.1
Ionis Pharmaceuticals Inc5,81718.911.418.7-21.7
Intellia Therapeutics Inc5,439-26.56.078.5345.3
10X Genomics Inc4,80750.04.979.8NA
Natera Inc4,71848.56.563.1491.0
Arrowhead Pharmaceuticals Inc4,690195.65.772.82,310.9
Beam Therapeutics Inc4,428251,025.05.946.4NA
Denali Therapeutics Inc4,083-75.67.1105.9NA
Mirati Therapeutics Inc3,992495.313.361.71,395.4
Ultragenyx Pharmaceutical Inc3,754-7.014.2109.0-15.3
Abcam PLC3,57320.30.917.727.4
Galapagos NV3,4863.613.220.7-19.2
PTC Therapeutics Inc3,41132.316.04.3142.1
Fate Therapeutics Inc3,18342.28.7129.91,016.0
Twist Bioscience Corp2,58944.33.6-9.8NA
Sage Therapeutics Inc2,140-99.414.764.4-58.6
Allogene Therapeutics Inc1,956-99.511.598.2NA
Iovance Biotherapeutics Inc1,892NA14.9126.2115.0
CareDx Inc1,30439.46.3102.71,601.4
Pacific Biosciences of California Inc1,16931.914.8127.129.9
Invitae Corp45650.6101.7181.4-80.8
Aggregate / median323,73831.96.854.087.0
Source: Bloomberg and Saxo Group

Why is the protein folding problem so important?

In a recent podcast interview with Lex Friedman, Demis Hassabis (co-founder of DeepMind) describes why protein folding is such an important problem to solve. Proteins are the building blocks of life and our bodies and are responsible for most of what happens inside cells. Drugs for curing a disease attach to certain proteins and therefore you have to know their 3D shape to design the drug properly. With AlphaFold biologists can now look up the same of a protein in the database instead of using eight years on average, in some cases scientists have given up on finding certain protein structures, to determine the structure. It will turbocharge drug discovery and protein design.

The graphics below show how much better AlphaFold is relative to the competition in predicting protein structures with a score above 90 being on par with experimentally determined structures.

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo Capital Markets HK Limited holds a Type 1 Regulated Activity (Dealing in securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged foreign exchange trading); Type 4 Regulated Activity (Advising on securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong

By clicking on certain links on this site, you are aware and agree to leave the website of Saxo Capital Markets, proceed on to the linked site managed by Saxo Group and where you will be subject to the terms of that linked site.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

Please note that the information on this site and any product and services we offer are not targeted at investors residing in the United States and Japan, and are not intended for distribution to, or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. Please click here to view our full disclaimer.